Inglis Tiffany Eul Davis
Chief Medical Officer
Inglis Tiffany Eul Davis has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Oct 13, 2026.
On the most recent filing, Inglis Tiffany Eul Davis is listed as Chief Medical Officer at SERA PROGNOSTICS, INC. Inside the rolling window, Inglis Tiffany Eul Davis reported no open-market purchases and 3 open-market sales totaling $18K in SERA. The largest disclosed transaction in the window is a sale of 8,024 SERA shares on Oct 12, 2026, worth $16K.
Companies traded
Other insiders at SERA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$18K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Inglis Tiffany Eul Davis made?
Inglis Tiffany Eul Davis has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company since 2025.
Which companies does Inglis Tiffany Eul Davis trade?
Inglis Tiffany Eul Davis has filed SEC Form 4 disclosures for 1 company, including SERA.
When was Inglis Tiffany Eul Davis's most recent SEC Form 4 filing?
Inglis Tiffany Eul Davis's most recent SEC Form 4 filing on Tracefour is dated Oct 13, 2026.
What is Inglis Tiffany Eul Davis's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Inglis Tiffany Eul Davis is listed as Chief Medical Officer.
What is Inglis Tiffany Eul Davis's total buy and sell value in the current window?
Inside the rolling retention window, Inglis Tiffany Eul Davis bought $0 and sold $18K based on SEC Form 4 filings.
What was Inglis Tiffany Eul Davis's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 8,024 SERA shares on 2026-10-12, worth $16K, per SEC Form 4 filings.